BioMarin Pharmaceutical Inc., a global biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions, has announced its financial results for 2019.
From the Key Program Highlights:
On 14 November 2019, BioMarin introduced its third gene therapy candidate, BMN 331, for the treatment of HAE. The company plans to build on its ever wider and deeper experience in developing gene therapies for severe hemophilia A and phenylketonuria to improve efficiencies in the development process and optimize capsid and transgene design. BioMarin expects to begin IND-enabling studies in early to mid-2020.
(Source: BioMarin)
